Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort

BACKGROUND: Tocilizumab and baricitinib are recommended treatment options for hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and safety in a head-to-head comparison is scarce. METHODS: Hospitalized COVID-19 patients requiring oxygen were treated with tocilizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Karolyi, Mario, Gruebl, Andreas, Omid, Sara, Saak, Magdalena, Pawelka, Erich, Hoepler, Wolfgang, Kelani, Hasan, Kuran, Avelino, Laferl, Hermann, Ott, Clemens, Pereyra, David, Santol, Jonas, Seitz, Tamara, Traugott, Marianna, Assinger, Alice, Wenisch, Christoph, Zoufaly, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461450/
https://www.ncbi.nlm.nih.gov/pubmed/36083403
http://dx.doi.org/10.1007/s15010-022-01915-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461450/
https://www.ncbi.nlm.nih.gov/pubmed/36083403
http://dx.doi.org/10.1007/s15010-022-01915-7

Ejemplares similares